333 related articles for article (PubMed ID: 9774334)
1. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.
Mohammadi M; Froum S; Hamby JM; Schroeder MC; Panek RL; Lu GH; Eliseenkova AV; Green D; Schlessinger J; Hubbard SR
EMBO J; 1998 Oct; 17(20):5896-904. PubMed ID: 9774334
[TBL] [Abstract][Full Text] [Related]
2. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
3. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
5. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
6. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.
Hagedorn M; Zilberberg L; Lozano RM; Cuevas P; Canron X; Redondo-Horcajo M; Gimenez-Gallego G; Bikfalvi A
FASEB J; 2001 Mar; 15(3):550-2. PubMed ID: 11259363
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development.
Magnusson P; Rolny C; Jakobsson L; Wikner C; Wu Y; Hicklin DJ; Claesson-Welsh L
J Cell Sci; 2004 Mar; 117(Pt 8):1513-23. PubMed ID: 15020678
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin.
Pellegrini L; Burke DF; von Delft F; Mulloy B; Blundell TL
Nature; 2000 Oct; 407(6807):1029-34. PubMed ID: 11069186
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
11. Flk-1 as a target for tumor growth inhibition.
Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
[TBL] [Abstract][Full Text] [Related]
12. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
15. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
16. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
17. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
18. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]